Sales of drugs and contrast agents in the U.S. drove German pharmaceuticals maker Schering to what it called an “exceptionally good” first quarter 2000, the company said last week.U.S. sales grew by 49% to 231 million euros, accounting for 22%
Sales of drugs and contrast agents in the U.S. drove German pharmaceuticals maker Schering to what it called an exceptionally good first quarter 2000, the company said last week.
U.S. sales grew by 49% to 231 million euros, accounting for 22% of Scherings total sales, which were reported up 25% to 1.044 billion euros. Net profit was up 22% to 106 million euros ($97.5 million) in the period from January to March.
The companys diagnostics division, which is one of the worlds largest makers of contrast agents, showed a sales increase of 27% to 295 million euros. Schering also makes a best-selling multiple sclerosis drug, Betaferon, and is a leading manufacturer of contraceptives and fertility drugs.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.